Takeda India has announced the appointment of Koki Sato as the Country Head for the company’s India business. In his current capacity, he will lead the company’s operations with a focus on the expansion of patient access to Takeda’s highly innovative portfolio in the country.
Sato joined Takeda in 2003 and, since then, grew within the company to hold various senior international roles across multiple functions, including commercial operations, finance, and HR. Prior to this role, Sato was the General Manager of Ukraine, Belarus and Moldova (UBM) Cluster in Takeda’s (ICMEA) area — India, the Commonwealth of Independent States, the Middle East (including Turkey) and Africa.
Sato said, “India is of significant importance for Takeda and we endeavour to develop initiatives which will lead to enhanced patient access to our highly innovative medicines locally. We remain committed to serving India’s patients, and aim to bring newer therapies for rare diseases, gastroenterology, and oncology to them in the coming years, along with hopefully, our Dengue vaccine candidate.”
Across its ICMEA area, and more broadly across the countries that span its growth and emerging markets business unit, Takeda collaborates with healthcare providers, governments and regulators, to ensure that its portfolio of innovative medicines is made available to patients as quickly and safely as possible.
Sato is a Japanese national and holds a Bachelor of Arts degree in Political Science and Economics from Waseda University, Japan.
Takeda India is part of Takeda Pharmaceutical Company Limited’s group of companies, headquartered in Japan. In the country, the company currently focuses on the therapeutic areas of Rare Diseases, including Hemophilia and Lysosomal Storage Disorders and plasma-derived therapies. Takeda has a presence across the Indian subcontinent, including in Sri Lanka, Nepal and Bangladesh.